Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche To Make Further In-Roads With Evrysdi In Newborn And Older SMA Patients

50% Of Older US Patients Untreated

Executive Summary

Roche’s Evrysdi is set to expand its license into pre-symptomatic children this year but the company is also focused on how to get greater numbers of older patients to seek treatment.

You may also be interested in...



It Takes A Village: Roche’s India Rare Disease Approach, Crowdfunding Support

Roche Pharma India CEO and managing director, V Simpson Emmanuel, outlines the company's multi-forked approach, including collaborating with a crowdfunding platform, to move the access and treatment needle for Evrysdi in India. The Swiss firm, along with industry associations, also suggests the need for a formal accelerated regulatory pathway in India for rare diseases.

Allogene May Have Cracked The Off-The-Shelf CAR-T Problem

Allogeneic candidate’s durability is holding up thanks to a novel conditioning regimen, but Phase II data will be crucial test.

Antibody-Drug Conjugates Take Their Place On The ASCO 2023 Stage

Investment from big and small players against existing and novel targets is making antibody-drug conjugates one of the fastest-growing fields in oncology, as attested by their presence at the upcoming ASCO meeting.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC146073

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel